Aphria Inc

Cannabis stocks have underperformed the broader markets. Despite the underperformance, Aphria’s recent financial performance was impressive.

Hexo (TSE:HEXO) has been struggling for a while now and things aren’t looking good. The stock has lost close to 70.2% year-to-date.

Marijuana is gaining a lot of attention amid the coronavirus pandemic. Many people think that Joe Biden should support marijuana legalization.

Medical marijuana legalization won’t happen in Idaho in 2020 due to the coronavirus pandemic. The ICC couldn’t gather the required signatures.

New York lawmakers decided to delay marijuana legalization due to the COVID-19 pandemic. As a result, New York won’t see marijuana legalization in 2020.

Hexo (TSE:HEXO) reported its second-quarter earnings on March 30. For the quarter, the company missed analysts’ revenue expectations marginally.

Amid the coronavirus pandemic, marijuana has become an essential item in many US states. As a result, there was a surge in cannabis demand.

The Tennessee Senate passed a medical marijuana bill due to the rising benefits of medical marijuana. However, the bill includes a poison pill.

The marijuana legalization process in US states is speeding up in 2020. Many new states are coming up with their own proposals to legalize marijuana.

Canopy Growth will report its earnings for the third quarter of fiscal 2020 before the market opens on Friday. Analysts expect the revenue to rise.

Tulsi Gabbard has been a big supporter of marijuana legalization. Recently, she spoke about how she wants all illicit drugs to be legal and not just marijuana.

Most US states are looking forward to cannabis legalization in 2020. Recently, Governor Andrew Cuomo promised to legalize cannabis in New York in 2020.

On January 10, HEXO was trading at 1.74 Canadian dollars, a fall of 63.1% since the beginning of 2019 and a discount of 84.6% to its 52-week high.

Cronos Group (CRON) stock rose 33% with a heavy volume in after-hours trading on Wednesday. Marijuana stocks are on a rollercoaster ride.

Aphria impressed analysts and cannabis investors in 2019. While the cannabis sector’s struggles pulled down Aphria stock, the company did well overall.

Aurora Cannabis (ACB) has had a tough year. The stock is down 63.1% in 2019. Let’s see how analysts have lowered their expectations for it in recent months.

Donald Trump has never openly supported marijuana legalization, and this month, Trump has shared some conflicting views on medical marijuana legalization.

Cannabis retailer MedMen Enterprises (MMNFF) has partnered with Onfleet software to handle its multistate logistics.

Aurora Cannabis’s Q1 cash cost of production fell to 0.85 Canadian dollars. Aurora credited its Sky facility’s cost-efficient cannabis cultivation.

Recreational marijuana is now legal in Michigan. It took the step in 2018, but the licensing process and regulations took awhile.

We’ve previously discussed the varying degrees of marijuana legalization in a variety of US states. Now, let’s talk about the laws in Hawaii.

Jim Cramer expressed disappointment with the cannabis industry, claiming it may not be the “incredible opportunity” he thought it was.

Aurora Cannabis reported its third-quarter results after the market closed on November 14. Despite some positives, it fell 18% on November 15.

Legal cannabis in Mexico is going through several twists and turns. The country first allowed medical marijuana in June 2017.

Charlotte’s Web Holdings (CWEB) (CWBHF) will report third-quarter earnings before the market opens on November 13. Let’s look at analysts’ expectations.

Media reports indicate that Angela Merkel’s party may consider legalizing cannabis in Germany. Medical marijuana has been legal in Germany since 2017.

Cannabis is an evolving sector. Recently, Warren Buffett entered the space following Kraft Heinz’s (KHC) newest investment in Flowhub.

Cannabis regulation in Mexico is a key topic this week. The US, Canadian, and Mexican economies are more closely intertwined than other countries.

Aurora Cannabis posted its fourth-quarter earnings after the market closed on Wednesday. The company posted revenues of 98.9 million Canadian dollars.

Aurora Cannabis (ACB) stock has been rising before its fourth-quarter earnings on Thursday. The stock has risen 12.4% this month.

HEXO stock has suffered since it reported lower-than-expected third-quarter results in June. The stock has fallen 31.8% since its earnings on June 12.

CannTrust (CTST) was hit with selling pressure this morning as its stock declined almost 5%. However, the overall cannabis sector seems to be positive

HEXO reported its third-quarter earnings on June 12. The company reported revenues of $13.0 million, which fell short of analysts’ estimate.

Marijuana reform is central to Beto O’Rourke’s 2020 presidential campaign—how could his agenda that affect the cannabis industry?

Canopy Growth’s weak results weighed on the entire cannabis sector. Most of the cannabis stocks were in the red on Thursday.

Cresco Labs (CRLBF) is set to report its Q2 earnings on August 21 after the market closes. The company’s stock fell 5.3% yesterday.

Charlotte’s Web Holdings stock (CWBHF)(CWEB) was down 6.6% yesterday after the company reported lower-than-expected Q2 earning results.

CNN reported that heavyweight champion Mike Tyson said they smoke 10 tons of weed, worth about $40,000, at his California marijuana ranch per month.

Today, MedMen Enterprises (MMEN) (MMNFF) reported its unaudited revenue for the fourth quarter of fiscal 2019.

Canopy Growth (CGC) rose 1.5% today while Cronos Group (CRON) fell 3.8%. CNBC host Jim Cramer favors both stocks amid several weed industry scandals.

Joe Biden wants to change the criminal justice system because he “believes no one should be in jail because of cannabis use.”

Canopy Growth (WEED)(CGC) is set to announce its fiscal 2020 first-quarter results on August 14. Market participants are eager to see how it did.

Aphria (APHA) reported its earnings results for Q4 and fiscal 2019 after the market closed today. Will the positive results lift cannabis sentiment overall?

Tilray (TLRY) is turning out to be one of the worst performers among the cannabis sector players with a YTD loss of 16%.

On April 3, Georgia’s state assembly approved a bill to legalize the production and sale of marijuana, which will be strictly for medicinal purposes.

In the second quarter, HEXO (HEXO) had total assets of 446 million Canadian dollars, which increased year-over-year from 334 million Canadian dollars.

In the first half of January 14, Tilray (TLRY) was up 6.8% as of noon. The stock continued its upward momentum after it received a boost last week.